Advertisement
U.S. markets open in 1 hour 18 minutes
  • S&P Futures

    5,137.75
    -8.25 (-0.16%)
     
  • Dow Futures

    39,017.00
    -125.00 (-0.32%)
     
  • Nasdaq Futures

    18,330.00
    -8.25 (-0.04%)
     
  • Russell 2000 Futures

    2,089.90
    +11.70 (+0.56%)
     
  • Crude Oil

    79.83
    -0.14 (-0.18%)
     
  • Gold

    2,091.20
    -4.50 (-0.21%)
     
  • Silver

    23.35
    -0.01 (-0.06%)
     
  • EUR/USD

    1.0850
    +0.0011 (+0.10%)
     
  • 10-Yr Bond

    4.1800
    0.0000 (0.00%)
     
  • Vix

    13.51
    +0.40 (+3.05%)
     
  • GBP/USD

    1.2676
    +0.0021 (+0.16%)
     
  • USD/JPY

    150.4860
    +0.4220 (+0.28%)
     
  • Bitcoin USD

    65,294.24
    +2,921.08 (+4.68%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,638.16
    -44.34 (-0.58%)
     
  • Nikkei 225

    40,109.23
    +198.41 (+0.50%)
     

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

Royalty Pharma plc
Royalty Pharma plc

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET.

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 12 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6637
ir@royaltypharma.com


Advertisement